Adia Nutrition Inc. Plans to Initiate Four to Five New Clinical Studies in 2026, Including Expansions in Autism and New Rheumatoid Arthritis Research

Core Insights - Adia Nutrition Inc. is expanding its clinical research pipeline with plans to launch four to five new studies in 2026, focusing on regenerative therapies using Adia Vita, which is derived from umbilical cord blood [1][4]. Clinical Research Expansion - The planned studies will be conducted at the Adia Med clinic in Winter Park, Florida, and in collaboration with partner clinics across the U.S. [3] - The company is actively seeking Institutional Review Board (IRB) approvals to facilitate multi-site participation for these studies [3][4]. Focus Areas of New Studies - Priority efforts include expanding the existing Autism Spectrum Disorder (ASD) study to include children aged 13, and launching a new study on the effects of Adia Vita in patients with rheumatoid arthritis [8]. - The ongoing ASD study is actively recruiting children aged 3-12 and has received IRB approval [4]. Business Model and Revenue Generation - Adia Nutrition generates revenue through service fees, product sales, equity stakes, and billing insurance for healthcare treatments [9]. - The company is also investing in aligned businesses, such as Cement Factory LLC, to enhance its focus on health and wellness [9]. Commitment to Ethical Standards - All research conducted by Adia Med is under strict ethical oversight, informed consent, and regulatory compliance [5]. - The company emphasizes its commitment to advancing regenerative medicine through rigorous and ethical clinical research [4]. Strategic Partnerships - Adia Med is open to strategic partnerships with clinic owners and healthcare practitioners interested in licensing its name or integrating its regenerative therapies into their practices [6]. - Collaborations with leading clinics are aimed at accelerating IRB approvals and broadening patient access [4].